 I. To determine the toxicity of the combination of CCI 779 and Bevacizumab in patients with metastatic renal cell cancer. Phase II II. To determine the clinical response rate of CCI 779 and Bevacizumab in patients with metastatic renal cell cancer. Phase II III. To determine the time to progression TTP, disease free survival, and overall survival of CCI 779 and Bevacizumab in patients with metastatic renal cell cancer. Phase II 